Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Collaborating with Florey Institute on Mass Spec Methods for Study of Metalloproteins

Premium

Agilent said this week that it will collaborate with Australia's Florey Institute of Neuroscience and Mental Health on methods for measuring metals at the protein level in tissue affected by neurodegenerative diseases including motor neuron, Parkinson's, and Alzheimer's.

The collaboration will focus on developing techniques for improved measurement of metalloproteins via liquid chromatography combined with Agilent's 7700 ICP-MS instrumentation. These techniques will allow Florey researchers to compare metalloprotein levels in samples of interest and investigate the range of metalloproteins present in these samples.

While metals and metalloproteins are thought to play a role in neurodegenerative processes, researchers have little data on how changes in the level of metals like copper, iron, and zinc at the protein level translate to changes in cellular function or disease state.

"This is an important breakthrough for the scientific community as we push forward for more effective treatments for a range of neurological and psychiatric conditions," Blaine Roberts, senior research scientist at the Florey, said in a statement.

"We are very excited about this collaboration, as it matches the leading-edge brain research of the Florey and Agilent's leading-edge technologies," said Rod Minett, general manager of Agilent's Life Sciences Group in South Korea and the South Asia-Pacific region. "The emerging field of metalloproteins will help us better understand the human brain and could potentially lead to better clinical outcomes for patients."

Financial and other terms of the agreement were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.